瑞丰高材(300243) - 300243瑞丰高材投资者关系管理信息

Group 1: PVC Additives - PVC additives prices have increased due to rising raw material costs, with demand showing signs of recovery and sufficient orders on hand [2][3] - The company has established itself as a leading player in ACR and MBS, with advantages in R&D, scale, and product quality [3] Group 2: Engineering Plastics Additives - The company’s engineering plastics additives include PC/ABS alloy toughening agents, ABS high rubber powder, and ASA rubber powder, with a current capacity of 10,000 tons/year [4] - Revenue from engineering plastics additives reached CNY 107 million in 2024, a 212.46% increase from 2023, and CNY 67.23 million in the first half of 2025, an 82.49% year-on-year growth [4] Group 3: Expansion Plans - A new project for engineering plastics additives with a capacity of 60,000 tons/year is underway, planned in two phases, with the first phase of 20,000 tons expected to be operational by the end of 2026 [4][5] - The project aims to enhance product variety and achieve domestic substitution for imported products, potentially improving profit margins [5] Group 4: Epoxy Resin Toughening Agents - Epoxy resin toughening agents are crucial for applications in automotive, wind power, and PCB boards, with high technical content and production difficulty [6] - The company is currently in small-scale production and aims to scale up following the completion of the engineering plastics additives project [6] Group 5: PBAT to PETG/PCTG Transition - The company is converting its existing PBAT project to produce high-end polyester materials PETG/PCTG, with a planned capacity of 30,000 tons/year expected to start mid-2026 [7] - Successful operation of this project could enhance revenue and mitigate fixed asset depreciation, although it faces uncertainties [7] Group 6: Black Phosphorus and Battery Adhesives - Black phosphorus is being developed for applications in batteries, flame retardants, and semiconductors, with a pilot production line expected to start in Q1 2026 [8] - The battery adhesive business is in the early stages, with plans to leverage existing MBS production lines for SBR synthesis, but currently lacks significant revenue impact [9] Group 7: Synthetic Biology Business - The synthetic biology segment focuses on developing materials like polylactic acid and has begun external sales of dextran, with plans to expand capacity by 2026 [9] - This segment is also in its early stages and is not expected to significantly impact revenue in the short term [9]